ZNTL

#3404
Zentalis Pharmaceuticals, Inc. - common stock
3.7 1 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.71
3.71
Intervallo Annuale
1.21
6.95
Variazione giornaliera
-1.33%
Variazione Mensile
-22.55%
Variazione di 6 mesi
+53.94%
Variazione Annuale
+119.53%
Chiusura Precedente
3.7 6
Open
3.7 1
Minimo
3.7 1
Massimo
3.7 1
Volume
40
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Zentalis Pharmaceuticals, Inc. current report, Q2 FY2023

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Zentalis Pharmaceuticals, Inc. (ZNTL) covers events occurring on June 16, 2023, specifically the Company's 2023 Annual Meeting of Stockholders. The filing details corporate governance actions, including the election of directors, the ratification of auditors, and amendments to the Certificate of Incorporation.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Voting Results

At the Annual Meeting, 55,773,072 shares (approximately 93.81% of outstanding stock) were present. The following material outcomes were reported:

  • Director Elections: David Johnson and Jan Skvarka, Ph.D. were elected as Class III Directors.
  • Accounting Firm: The appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified.
  • Corporate Amendment: Stockholders approved an amendment to the Certificate of Incorporation to update the exculpation provision for certain officers in compliance with recent Delaware General Corporation Law amendments.
  • Executive Compensation: The advisory proposal to approve the compensation of named executive officers was not approved, with 34,337,776 votes cast against the proposal compared to 18,723,776 votes in favor.

Guidance, Outlook, and Risks

The filing does not contain management commentary on financial guidance, future outlook, or specific business risks. The primary risk highlighted by the voting results is the significant shareholder dissent regarding executive compensation, which may signal a need for the Board to review its compensation strategy.

Key Facts for Investor Verification

  • Verify the specific details of the failed executive compensation vote and any subsequent Board response or communication regarding compensation policy.
  • Review the full text of the Certificate of Amendment (Exhibit 3.1) to understand the scope of the updated exculpation provisions for officers.
  • Confirm the tenure and background of the newly elected Class III directors, David Johnson and Jan Skvarka, Ph.D.
  • Check subsequent filings for any updates on the Company's financial status, as this 8-K contains no financial data.

Notizie